Article Navigation
Article Contents
-
Declarations
-
References
- < Previous
- Next >
Journal Article
, Héctor Bueno Centro Nacional de Investigaciones Cardiovasculares (CNIC), Hospital Universitario 12 de Octubre , Melchor Fernández Almagro, 3, 28029 Madrid , Spain Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) , Madrid , Spain Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV) , Madrid , Spain Facultad de Medicina, Universidad Complutense de Madrid , Madrid , Spain Corresponding author. Tel: +34 914 53 12 00, Fax: +34 91 453 1245, Email: hbueno@cnic.es Search for other works by this author on: Oxford Academic Milton Packer Baylor Heart and Vascular Institute, Baylor University Medical Center , Dallas, TX , USA Search for other works by this author on: Oxford Academic
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
Author Notes
European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3683–3685, https://doi.org/10.1093/eurheartj/ehad560
Published:
25 August 2023
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Héctor Bueno, Milton Packer, Acetazolamide for acute heart failure: is ADVOR a riddle wrapped in a mystery inside an enigma?, European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3683–3685, https://doi.org/10.1093/eurheartj/ehad560
Close
Search
Close
Search
Advanced Search
Search Menu
Graphical Abstract
Open in new tabDownload slide
Inability of diuresis and natriuresis to explain the reported effect of acetazolamide in alleviating physical signs of congestion. Abbreviations: eGFR = estimated glomerular filtration rate.
This editorial refers to ‘Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial’, by E. Meekers et al., https://doi.org/10.1093/eurheartj/ehad557.
The main cause of worsening symptoms in acute heart failure (AHF) is pulmonary congestion. Such congestion may be the consequence of a redistribution of blood volume due to the effect of the sympathetic nervous system to cause venoconstriction.1 However, more commonly, congestion is related to sodium and water retention by the kidneys. Physical signs of congestion are typically seen only after the retention of at least 5 L of fluid.2 In the latter instance, treatments to achieve decongestion represent a cornerstone of the management of AHF.3 In most patients with AHF, systemic decongestion can be achieved by loop diuretics, which promote an important increase in urinary sodium excretion and urinary volume. If low doses of loop diuretics are insufficient, patients often respond to higher doses of furosemide or torsemide.4,5
The Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial reported the effects of the administration of acetazolamide to hospitalized patients with acute decompensated heart failure already receiving a loop diuretic. When compared with placebo, acetazolamide 500 mg intravenously daily for 3 days was reported to produce an increase in cumulative urinary sodium excretion, an increase in total urinary volume, and a 12% absolute increase in the proportion of patients who were considered to have ‘complete decongestion’ at discharge.6 The use of acetazolamide was associated with 1 day shortening in the length of hospital stay, but this benefit was accompanied by a higher risk of transient worsening of renal function (WRF). Importantly, acetazolamide-treated patients did not have improved 3-month outcomes, assessed by the composite of heart failure hospitalization and all-cause mortality.
In this issue of European Heart Journal,7 the investigators of the ADVOR trial report the influence of baseline renal function on the effects of acetazolamine. They note that the effects of acetazolamide on cumulative urinary sodium excretion and total urinary volume during the treatment period were more pronounced among patients with an estimated glomerular filtration rate (eGFR) below the median eGFR in the study (≤40 mL/min/1.73 m2), as compared with those with eGFR > 40 mL/min/1.73 m2. However, and importantly, the eGFR value before treatment did not influence the degree of decongestion produced by acetazolamide, with a similar decongestive effect reported in patients with an eGFR >40 L/min/1.73m2 or ≤40 mL/min/1.73 m2.
These observations might appear to be encouraging. Patients with heart failure who have renal dysfunction are likely to exhibit diuretic resistance, potentially related to a decrease in the delivery of tubular sodium to the loop of Henle as a result of a decline in glomerular filtration.4 An action of acetazolamide to inhibit both carbonic anhydrase and sodium–hydrogen exchanger 3 in the proximal renal tubule might increase the distal delivery of sodium, specifically to the loop of Henle, thus enlarging the target for loop diuretics.4,8 Inhibition of sodium reabsorption in the proximal tubule could conceivably be more attractive than adding thiazides, which act primarily on the distal nephron, but whose use is often accompanied by hypokalaemia and WRF.9
However, the new analyses presented by the ADVOR investigators raise additional questions (Graphical Abstract). In the original ADVOR report, when all patients were considered in the analysis, the increases in cumulative urinary sodium excretion and total urinary volume were modest. In absolute terms, when compared with placebo, acetazolamide produced an increase in urinary sodium that averaged 97 mmol of excreted sodium and an increase in urinary volume of 0.5 L over 2–3 days. Patients with physical signs of congestion (evident as meaningful peripheral oedema, ascites, and pleural effusion) have retained at least 5 L of fluid.2 In these patients, resolution of congestion in an incremental 5%–10% of patients is typically accompanied by increases in urine volume in the active treatment group that exceed those in the control group by at least 1.5 L.5 Therefore, resolution of the signs of congestion in ADVOR (which reported a 12% absolute increase in decongestion) would have necessitated an incremental diuresis of at least 2.0–2.5 L of urine, rather than the 0.5 L treatment effect that was reported in ADVOR.6,7
Furthermore, in the new analyses,7 the 254 patients with an eGFR >40 mL/min/1.73 m2 were reported to have experienced no significant natriuresis or diuresis. When compared with placebo, the magnitude of the effect of acetazolamine on urinary sodium excretion averaged only 50 mmol, and the effect of the drug on total urinary volume was only 148 mL (Graphical Abstract). Neither of these effects was statistically significant, and both of these effects are physiologically trivial. Yet, the ADVOR investigators report that the patients with an eGFR >40 mL/min/1.73 m2 still experienced successful decongestion to a degree that was similar to those with impaired renal function. How is it possible for successful decongestion to be achieved without a drug-related increase in urinary sodium excretion or urinary volume?
Based on the new analyses, it seems unlikely that the physical decongestion reported in ADVOR was related to an effect of the drug to inhibit proximal renal tubular sodium reabsorption. Sodium–glucose co-transporter 2 (SGLT2) inhibitors also inhibit proximal renal tubular reabsorption, but their natriuretic effect is typically opposed by the counter-regulatory activation of sodium reabsorption in downstream nephron segments.8,10 That explains why empagliflozin did not increase urinary sodium excretion in two trials of patients with acute heart failure (EMPAG-HF and EMPA-RESPONSE-AHF).11–13 In a third trial (EMPULSE), clinical decongestion was reported after 15 days, but without any reported effect on urinary sodium or volume.14 Yet, in the EMPULSE trial, decongestion was assessed by symptoms, and not by physical signs. Furthermore, in that trial, treatment with empagliflozin was maintained for the duration of follow-up (i.e. 90 days), whereas in ADVOR treatment with acetazolamide was administered for only 2–3 days.
How can acetazolamide have achieved decongestion of physical signs in 2–3 days in the absence of meaningful changes in urinary sodium and volume? In ADVOR, before randomization, the determination that patients had congestion was based on the observation that they had more than trace oedema or evidence of a pleural effusion or ascites, which was determined by physical examination and confirmed by imaging, typically ultrasound.6 However, following randomization, the assessment of congestion was entirely dependent on the physical examination performed by the investigator, and no confirmatory imaging was performed. Although the investigator was blinded to the treatment assignment, physicians who were responsible for the assessment of the primary endpoint may have been aware of the effect of treatment on serum bicarbonate. Acetazolamide has a well-established effect on serum bicarbonate, which was measured in the ADVOR trial as a requirement of the protocol.6 The mean change in bicarbonate in the acetazolamide group need not have been large to have influenced the judgement of site investigators in a meaningful fraction of patients.15 This possibility might be one explanation for the resolution of physical signs of congestion in the absence of a natriuresis or diuresis in patients with preserved renal function.
Finally, it is important to consider the safety of acetazolamide. The authors conclude that acetazolamide is safe and effective to treat congestion across the entire range of renal function. However, as noted in the current report, use of the drug was accompanied by a three-fold increase in the risk of WRF. In their Supplementary material online, the investigators note that an elevated baseline serum creatinine further heightened the risk of worsening renal function. We do not know the consequence of WRF following acetazolamide in patients with an already impaired GFR. Yet, these are the patients that the investigators would particularly target for treatment with acetazolamide.7
In summary, the results of ADVOR are worthy of a famous saying by Winston Churchill, who described the events during the outbreak of the Second World War as being ‘a riddle wrapped in a mystery inside an enigma’, suggesting that additional time and thought was required to understand the course of events. As the analyses from ADVOR are reported, the same advice seems to apply. The effects of acetazolamide in patients with acute heart failure and congestion clearly require further study.
Declarations
Disclosure of Interest
All authors declare no conflict of interest for this contribution.
References
1
Fudim M Patel MR Boortz-Marx R Borlaug BA DeVore AD Ganesh A
Splanchnic nerve block mediated changes in stressed blood volume in heart failure
.
JACC Heart Fail
2021
;
9
:
293
–
300
2
Clark AL Cleland JGF
Causes and treatment of oedema in patients with heart failure
.
Nat Rev Cardiol
2013
;
10
:
156
–
170
3
McDonagh TA Metra M Adamo M Gardner RS Baumbach A Böhm M
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
.
Eur Heart J
2021
;
42
:
3599
–
3726
4
Felker GM Ellison DH Mullens W Cox Z Testani JM
Diuretic therapy for patients with heart failure: jACC state-of-the-art review
.
J Am Coll Cardiol
2020
;
75
:
1178
–
1195
5
Felker GM Lee KL Bull DA Redfield MM Stevenson LW Goldsmith SR
Diuretic strategies in patients with acute decompensated heart failure
.
N Engl J Med
2011
;
364
:
797
–
805
6
Mullens W Dauw J Martens P Verbrugge FH Nijst P Meekers E
Acetazolamide in acute decompensated heart failure with volume overload
.
N Engl J Med
2022
;
387
:
1185
–
1195
7
Meekers E Dauw J Martens P Dhont S Verbrugge FH Nijst P
Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial
.
Eur Heart J
2023
;
44
:
3672
–
3682
.
OpenURL Placeholder Text
8
Packer M Wilcox CS Testani JM
Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes
.
Circulation
2023
;
148
:
354
–
372
9
Trulls JC Morales-Rull JL Casado J Carrera-Izquierdo M Sánchez-Marteles M Conde-Martel A
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial
.
Eur Heart J
2023
;
44
:
411
–
421
10
Packer M
Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure
.
Cardiovasc Diabetol
2023
;
22
:
197
11
Schulze PC Bogoviku J Westphal J Aftanski P Haertel F Grund S
Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)
.
Circulation
2022
;
146
:
289
–
298
12
Boorsma EM Beusekamp JC Ter Maaten JM Figarska SM Danser AHJ van Veldhuisen DJ
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
.
Eur J Heart Fail
2021
;
23
:
68
–
78
13
Damman K Beusekamp JC Boorsma EM Swart HP Smilde TDJ Elvan A
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)
.
Eur J Heart Fail
2020
;
22
:
713
–
722
14
Voors AA Angermann CE Teerlink JR Collins SP Kosiborod M Biegus J
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
.
Nat Med
2022
;
28
:
568
–
574
15
Packer M Butler J
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: key insights into ADVOR and EMPULSE
.
Eur J Heart Fail
2023
. https://doi.org/10.1002/ejhf.2968
OpenURL Placeholder Text
Author notes
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
Issue Section:
FAST TRACK CLINICAL RESEARCH > Editorial
Download all slides
Advertisem*nt intended for healthcare professionals
Citations
Views
1,785
Altmetric
More metrics information
Metrics
Total Views 1,785
1,053 Pageviews
732 PDF Downloads
Since 8/1/2023
Month: | Total Views: |
---|---|
August 2023 | 217 |
September 2023 | 140 |
October 2023 | 806 |
November 2023 | 116 |
December 2023 | 147 |
January 2024 | 105 |
February 2024 | 62 |
March 2024 | 88 |
April 2024 | 71 |
May 2024 | 33 |
Email alerts
Article activity alert
Advance article alerts
New issue alert
Receive exclusive offers and updates from Oxford Academic
See also
-
Companion Article
- Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
More from Oxford Academic
Cardiovascular Medicine
Clinical Medicine
Medicine and Health
Books
Journals
Crows Nest, New South Wales
Lakeland, Florida
Burlington, Vermont
New Haven, Connecticut
Advertisem*nt intended for healthcare professionals